



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 4 : A61K 37/26		A1	(11) International Publication Number: WO 87/ 06137
			(43) International Publication Date: 22 October 1987 (22.10.87)
(21) International Application Number: PCT/DK87/00038		(74) Agent: DANSK PATENT KONTOR A/S: H.C. Ørsted eds Vej 70, DK-1879 Frederiksberg C (DK).	
(22) International Filing Date: 14 April 1987 (14.04.87)			
(31) Priority Application Number: 1792/86		(81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FI, FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), NO, SE (European patent), US.	
(32) Priority Date: 18 April 1986 (18.04.86)			
(33) Priority Country: DK			
(71) Applicant (for all designated States except US): NOR-DISK GENTOFTE A/S [DK/DK]; Niels Steensens Vej 1, DK-2820 Gentofte (DK).		Published With international search report.	
(72) Inventors; and (75) Inventors/Applicants (for US only) : BALSCHMIDT, Per [DK/DK]; Tibberup Alle 20, DK-3060 Espergærde (DK). HANSEN, Finn, Benned [DK/DK]; Østerbrogade 54 B, 4, DK-2100 Copenhagen (DK). JOHANSEN, Bente, Rose [DK/DK]; Garderhøjvej 24, DK-2820 Gentofte (DK).			

(54) Title: AN INSULIN PREPARATION FOR NON-PARENTERAL ADMINISTRATION



Insulin preparations for non-parenteral administration and containing one or more insulins or insulin derivatives, which in solution in the physiological pH range predominantly are present as monomers, usual additives and possibly a conventional insulin and possibly one or more absorption promoting substances provide a fast absorption of the insulin activity administered.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

An insulin preparation for non-parenteral administration.

TECHNICAL FIELD

The present invention relates to insulin preparations for non-parenteral administration.

5 BACKGROUND ART

Ever since the discovery of insulin and its successive use for the treatment of Diabetes the only form of administration used in practice has been subcutaneous or intramuscular injection, generally several times a day. In
10 spite of a rapid technical development, this administration still involves a number of disadvantages, such as pain, risk of infection as well as a possibility of chronic tissue injuries. Consequently, there has always been a wish to administer the insulin non-parenterally, and
15 thus in particular oral, rectal, nasal, as well as ophthalmic administrations have been investigated.

The ophthalmic administration of insulin has been disclosed in the specification of Danish Patent No. 135,268, according to which specification an insulin-containing
20 hydrogel is placed under the eyelid. Thereby an absorption of 5 - 20% of the amount of insulin administered is obtained over a period of several hours.

The oral administration demands that special protective measures are taken in order to prevent the insulin from
25 being decomposed, before absorption can take place through the intestinal mucosa. This can e.g. be done as stated in the specification of Danish patent application No. 1925/83 and Danish patent application No. 2294/84, according to which enzyme inhibitors are added and an encapsulation in
30 a bile-soluble material may be made. Oral administration only gives an absorption of 1-2% of the amount of insulin administered, cf. Galloway et al., Diabetes 21 (1971), pages 640-648.

Rectal insulin administration is disclosed in e.g. German Published Specification No. 2,641,819, U.S. Patent Specification No. 4,164,573 and U.S. Patent Specification No. 4,442,090. In this way of administration the insulin is
5 encapsulated in the form of a suppository in which the presence of an enzyme inhibitor is normally not necessary. Hereby an absorption of the amount of insulin administered of about 5% can be obtained.

In the forms of administration mentioned above use is made
10 in almost all cases of a surface-active additive to increase the absorption rate and efficiency of the insulin through the mucosae. An example of such absorption promoting adjuvants are polyoxy ethylene fatty alcohol ethers and in particular bile acids or salts thereof.

15 Such additives are particularly effective in nasal administration of insulin, vide GB Patent Specifications No. 1,527,605 and No. 1,554,157, and the technique has been further described by S. Hirai et al., Diabetes 27 (1978), pages 296-299, and G.S. Gordon et al., PNAS 82 (1985),
20 pages 7419-7423. In this form of administration the insulin is administered in solution as drops or better in atomized form to the nasal cavity, whereafter the absorption through the nasal mucosa occurs so rapidly that the maximum insulin concentration is obtained already after 10 to
25 30 minutes. This rapidly commencing absorption is of particularly therapeutical importance as the maximum insulin concentration in normal subcutaneous injection of dissolved insulin does not commence until after 30-60 minutes, which may cause problems in a much employed Diabetes therapy,
30 in which injections of rapidly acting insulin are given immediately before the principal meals.

However, in the nasal form of administration an adverse effect on the mucosae due to the added absorption promoting adjuvants has been demonstrated after some time, vide
35 S. Hirai et al., Int. J. Pharm. 9 (1981), pages 173-184.

This problem is said to be solved by the use of certain fusidic acid or cephalosporine derivatives as adjuvants, vide the specification of European patent application No. 128,831. The proportion of insulin absorbed by nasal
5 administration in dissolved and atomized form is said to be up to about 20% in the publications mentioned above.

An embodiment of the nasal administration in which the use of surface-active adjuvants can be avoided is known from European patent application No. 122,036. Said embodi-
10 ment consists in the administration of the insulin as a powder, whereby use is made of a water-insoluble, but water-absorbing carrier, e.g. crystalline cellulose. Hereby the particles adhere to the nasal mucosa, and moisture is absorbed which has the effect that the insulin attains
15 an intense contact with the mucosa and thereby can be absorbed with a high efficacy.

In all the known insulin preparations for non-parenteral administration a conventional commercially available insulin is used as the basis of the formulation. When such an
20 insulin is dissolved at physiological pH value a concentration-dependent equilibration is established between monomeric, dimeric, hexameric, and polymeric insulin. The degree of self-association can be determined e.g. by ultracentrifugation or by gel filtration methods, vide e.g.
25 R. Valdes Jr. and G.A. Ackers, "Methods in Enzymology", Vol. 61 (Enzyme Structure, part H, ed.: Hirs & Timasheff), Academic Press 1979, pages 125 - 142. In conventional commercially available preparations of dissolved insulin a very large proportion of the insulin is present as hexa-
30 mers.

DISCLOSURE OF THE INVENTION

By the use of insulins or insulin derivatives which in solution in the physiological pH range predominantly are present as monomers in insulin preparations for non-parenteral administration a still more rapid absorption of
35

the insulin activity administered is obtained, as maximum concentration in serum is attained already after 5-10 minutes.

The insulin preparations of this invention are characterized in that they contain one or more insulins or insulin derivatives which in solution in the physiological pH range predominantly are present as monomers and usual additives and, possibly, a conventional insulin and, possibly, one or more absorption promoting substances. The physiological pH range comprises pH values from about 6.5 to about 8.5.

In particular, the invention relates to an insulin preparation for non-parenteral administration, which preparation as the main insulin active component contains insulin derivatives which in solution in the physiological pH range predominantly are present as monomers.

In particular, the invention relates to insulin preparations for nasal administration.

Nasal insulin preparations may e.g. be dosed from a bottle equipped with a manual atomizer designed for delivering a specific volume of insulin solution per dose. Thus, the nozzle of the bottle is led into a nostril before the atomization which may be repeated in the other nostril.

Insulins or insulin derivatives which predominantly are present as monomers often exhibit reduced insulin activity. Thus, such insulins or insulin derivatives that still exhibit a considerable insulin activity, e.g. A1, B1, B29-trisuccinyl insulin, tetrakis-(3-nitrotyrosine)-insulin as well as des-pentapeptide(B26-30)-insulin, des-pentapeptide(B26-30)-insulin-B25-amide, and sulphated or phosphorylated insulin, are useful in the preparation of the invention.

Trisuccinyl insulin can be prepared by treating insulin with succinic acid anhydride (D.E. Massey, D.G. Smyth: Eur. J. Biochem. 31 (1972), pages 470-473); tetranitro-insulin can be obtained by reaction between insulin and tetranitro methane (F.H. Carpenter et al., Biochemistry (USA) 19 (1980), pages 5926-5931); despentapeptide-insulin is formed by digesting insulin with pepsin (H.G. Gattner: Hoppe-Seylers Z. Physiol. Chem. 356 (1975), pages 1397 - 1404); deseptapeptide-insulin amide can be prepared by condensing desoctapeptide insulin and gly-phe-phe-NH₂ by trypsin-assisted peptide bond formation (W.H. Fischer et al., Biol. Chem. Hoppe-Seyler 366 (1985), pages 521 - 525), and sulphated insulin may be obtained by reacting insulin with a carbodiimide in the presence of sulphuric acid (S. Pongor et al., Diabetes 32 (1983), pages 1087 - 1091, U.S. Patent Specification No. 4,534,894).

Useful absorption promoting substances are surface-active compounds, as e.g. fatty alkyl or fatty acyl substituted polyethyleneglycol, block copolymers of polyethyleneglycol and polypropyleneglycol, salts of bile acids, as e.g. taurocholic acid, deoxycholic acid and glycodeoxycholic acid, salts of N-acyl amino acids, as e.g. lauroyl sarcosine and palmitoyl glutamic acid, as well as derivatives of fusidic acid and cephalosporine. Particularly useful are such substances exhibiting the least possible tissue irritation.

Physiologically acceptable acids or bases of pH values near the physiological pH range can be used as buffers, e.g. phosphates, tris(hydroxymethyl)-aminomethane (TRIS) and glycyl glycine. Physiologically acceptable salts or polyhydroxy compounds can be used as isotonica, e.g. sodium chloride, glycerine or mannitol. Useful preserving agents comprise phenol or benzyl alcohol or similar substances being active in the physiological pH range.

Useful suppository vehicles in preparations for rectal administration are premixed synthetic fats, e.g.

"Witepsol" [®], or partly decomposed vegetable oils and fats or Macrogols.

- 5 In powdery preparations for nasal administration dried water-absorbing, but water-insoluble substances, e.g. cross-linked polyvinyl pyrrolidone or in particular crystalline cellulose having a particle size between 20 and 200 μm can be used as carriers.
- 10 Aqueous preparations intended for nasal administration generally contain 40 - 500 I.U. insulin activity per ml, preferably ranging from 80 to 300 I.U./ml. The content of surface-active absorption promoting substances is usually in the range of from 0.1 to 10%, and a content of
- 15 from 0.5 to 5% is preferred. The pH of the preparation should be near the physiological pH and a pH range between 7 and 8 is preferred.

Powders for nasal administration generally contain 0.5-10 I.U. insulin activity per mg, preferably 1-8 I.U./mg.

- 20 The insulin or insulin derivative used in these preparations should be prepared as an easily water-soluble product, preferably by lyophilization from solutions having a pH of between 6.5 and 8.5.

- Rectal insulin preparations in the form of suppositories
- 25 generally contain 2 - 200 I.U. insulin activity per gram, of which 5 - 100 I.U./gram is preferred. The absorption promoting substance is usually added in an amount of 0.1-25% by weight, and 0.5-10% (w/w) is preferred. The preparations are generally cast as suppositories of
- 30 0.5-3 grams, preferably weighing 1-2.5 grams.

MODES FOR CARRYING OUT THE INVENTION

The invention is further illustrated by the following Examples.

EXAMPLE I

5 Formulation of a preparation for rectal administration.

95 mg of trisuccinyl porcine insulin and 1.0 gram of sodium cholate were thoroughly mixed into 100 ml of melted "Witepsol" ^(R) at 36°C, and the resulting mass was cast in forms to suppositories of 2 ml, each containing 20 I.U. of insulin activity.

EXAMPLE II

Formulation of a preparation for nasal administration.

75 mg of des-pentapeptide(B26-30) porcine insulin-B25-amide were dissolved in 3 ml of water by means of a small amount of hydrochloric acid, whereafter 5 ml of 0.02 M sodium dihydrogen phosphate in 1% phenol were added. The pH value was adjusted to 8.5 with sodium hydroxide, and water was added until 10 ml. This solution was now mixed with 10 ml of a freshly produced 2% solution of sodium glycodeoxycholate in 0.25 M sodium chloride, adjusted to a pH value of 7.5 with hydrochloric acid and subsequently filled into a bottle, which was sealed with a manual atomizer delivering a specific volume of solution per puff. With a dosage volume of 100 µlitres 10 I.U. of insulin activity was thus administered through a single puff.

EXAMPLE III

Preparation of des-pentapeptide(B26-30) porcine insulin-B25-amide.

500 mg of des-octapeptide(B23-30) porcine insulin prepared

in a manner known per se by trypsin digestion of porcine insulin and 1000 mg of gly-phe-phe-NH₂ prepared in a manner known per se by Merrifield-synthesis were dissolved in a mixture of 6 ml of dimethylformamide and 3 ml of water, and the pH value was adjusted to 6.5 with triethylamine or acetic acid. A solution of 25 mg trypsin in 500 µl of 0.001 M calcium acetate was added with stirring, and the reaction mixture was left at 20°C for 4 hours. Then the proteins were precipitated from the solution by the addition of 100 ml of acetone and separated by centrifugation. The precipitate was redissolved in 20 ml of 1 M acetic acid, 7 M urea and gel-filtered on a 5 x 85 cm column of "Sephadex"® G 50 Superfine in 1 M acetic acid. The fractions containing the protein main fraction were collected and freeze-dried.

The freeze-dried protein was redissolved in 40 ml of 7 M urea, the pH value being adjusted to 8.1 with 1 M TRIS and applied to a 2.6 x 20 cm column of DEAE-cellulose ("Whatman"® DE-52), packed and equilibrated in 0.02 M TRIS/hydrochloric acid, 7 M urea pH value 8.1. Thereafter the column was eluted at 4°C with a sodium chloride gradient from 0.1 M in the same buffer over 48 hours at a flow of 40 ml per hour. The fractions containing the protein main peak first eluted were collected and desalted on "Sephadex"® G 25 Fine in 1 M acetic acid. The proteinaceous pool was freeze-dried.

Yield: 260 mg of des-pentapeptide(B26-30) porcine insulin-B25-amide.

EXAMPLE IV

30 Preparation of trisuccinyl human insulin.

250 mg of Zn-free semisynthetically prepared human insulin were dissolved in 12.5 ml of 0.5 M TRIS/acetic acid, 7 M urea pH 8.5, whereafter 25 mg of succinic anhydride

were added with stirring. The mixture was left with stirring for 1 hour at 20°C. Thereafter the reaction mixture was desalted on "Sephadex"® G 25 in 0.05 M ammonium hydrogen carbonate, and the proteinaceous fractions were freeze-dried. The freeze-dried substance was dissolved in 1.5 M acetic acid, 0.05 M sodium chloride, 7 M urea and applied to a 2.6 x 20 cm column of SP-"Sephadex"® C-25, packed and equilibrated in the same buffer. Then there was eluted with a 0.05 → 0.2 M sodium chloride gradient over 24 hours at a flow of 40 ml per hour at 4°C. The protein main peak first eluted was collected and desalted on "Sephadex"® G 25 in 0.05 M ammonium hydrogen carbonate. The proteinaceous eluate was freeze-dried.

Yield: 125 mg of trisuccinyl human insulin.

15

EXAMPLE V

Preparation of sulphated porcine insulin.

250 µlitres of concentrated sulphuric acid were added dropwise with stirring to 4.75 ml of ice-cold anhydrous dimethyl formamide, whereupon 100 mg of Zn-free porcine insulin were dissolved therein with continued stirring. 500 mg of dicyclohexylcarbodiimide dissolved in 1 ml of dimethyl formamide were added, and the mixture was shaken at 4°C for 6 hours. Hereafter about 5 grams of crushed ice were added, and the mixture was neutralized with 10 N sodium hydroxide solution. 10 ml of water were added, and the precipitated dicyclohexyl urea was separated by centrifugation. Thereafter the supernatant was desalted on a "Sephadex"® G 25 column in 0.05 M ammonium hydrogen carbonate solution and freeze-dried.

Yield: 80 mg of sulphated porcine insulin.

EXAMPLE VI

Formulation of a preparation for nasal administration.

70 mg of sulphated porcine insulin were dissolved with stirring in 10 ml of 0.14 M of sodium chloride containing
5 1% of sodium-tauro-24,25-dihydro-fusidate and 0.3% m-cresol, the pH value being adjusted to 7.4. Hereby a preparation containing 150 I.U. of insulin activity per ml is obtained, which preparation is particularly suitable for administration from a spray dosage container due to the
10 good shaking stability of the insulin derivative

EXAMPLE VII

Formulation of a preparation for nasal administration.

100 mg of des-pentapeptide (B26-30) porcine insulin-B25-
-amide were dissolved in 20 ml of water with the pH value
15 being adjusted to 7.5 with sodium hydroxide, and the solution was freeze-dried. The resulting insulin powder was thoroughly mixed in a mortar with 800 mg of crystalline cellulose so as to obtain a uniform powder composition containing 3 I.U. of insulin activity per mg.

20 Thereafter the nasal powder can be administered to the nasal mucosa by means of an insufflator, which may be designed in such a way that the powder is administered as a dosed medicine in the form of a gelatine capsule being perforated immediately before the insufflation.

25

EXAMPLE VIII

In vivo experiments.

Male, 6 weeks old, Wistar rats ($150 \pm$ grams) made diabetic 3 days prior by intravenous injection of strepto-

zotocin (65 mg/kg) were anaesthetized with pentobarbital (50 mg/kg) intraperitoneally, and polythene catheters were inserted into a carotid artery for blood sampling. A tracheal cannula was inserted in the rats before the
5 intranasal insulin administration.

Groups of 4 rats were dosed intranasally at 0 min. with 10 µlitres of one of the following preparations:

- A. 250 I.U./ml of Zn-insulin (human)
1/75 M sodium phosphate
10 1.6% (vol/vol) of glycerol
1.0% (weight/vol) of sodium glycodeoxycholate
- B. 250 I.U./ml of des-pentapeptide (B26-30) porcine insulin-B25-amide
1/75 M sodium phosphate
15 1.6% (vol/vol) of glycerol
1.0% (weight/vol) of sodium glycodeoxycholate
- C. 1/75 M sodium phosphate
1.6% (vol/vol) of glycerol
1.0% (weight/vol) of sodium glycodeoxycholate
- 20 250 µlitres of blood were sampled into heparinized ice-cold tubes at -5, 10, 20, 40, 60, 90, and 120 minutes, and the plasma samples were frozen after centrifugation for later insulin determination by radioimmunoassay.

Table I and Fig. 1 depict the plasma insulin levels (means and S.E.M.) at the various sampling times. The detection
25 limit is 0.05 nmol/litre.

It can be seen that the monomeric des-pentapeptide insulin-amide (B) was absorbed faster and more reproducibly than the conventionally used hexameric insulin (A).

TABLE I

		Plasma insulin concentration (nmol/litre)									
Preparation	No. of rats	minutes after administration									
		-5	10	20	40	60	90	120			
A (Zn-insulin)	4	\bar{x}	18.07	18.14	16.32	5.97	3.21	1.21			
		\pm S.E.M.:	± 6.81	± 6.87	± 6.42	± 2.17	± 0.99	± 0.34			
B (DPI-amide)	4	\bar{x}	59.39	19.46	7.13	3.88	1.42	0.96			
		\pm S.E.M.:	± 14.25	± 2.74	± 1.83	± 1.17	± 0.46	± 0.26			
C (placebo)	4	\bar{x}	<0.05	<0.08	<0.07	<0.06	<0.08	<0.09			
		\pm S.E.M.:									

CLAIMS

1. Insulin preparation for non-parenteral administration, c h a r a c t e r i z e d by containing one or more insulins or insulin derivatives, which in solution in the
5 physiological pH range predominantly are present as monomers, and usual additives as well as possibly a conventional insulin and possibly one or more absorption promoting substances.
2. Insulin preparation according to claim 1, c h a r -
10 a c t e r i z e d by containing as the main insulin active component insulins or insulin derivatives, which in solution in the physiological pH range predominantly are present as monomers.
3. Insulin preparation according to claim 1, c h a r -
15 a c t e r i z e d by being a preparation for nasal administration.
4. Insulin preparation according to claims 1-3, c h a r a c t e r i z e d in that the insulin derivative is des/(B26-30)-pentapeptide/insulin-B25-amide.
- 20 5. Insulin preparation according to claims 1-3, c h a r a c t e r i z e d in that the insulin derivative is des/(B26-30)-pentapeptide/insulin.
6. Insulin preparation according to claims 1-3, c h a r a c t e r i z e d in that the insulin derivative
25 is A1,B1,B29-trisuccinyl insulin.
7. Insulin preparation according to claims 1-3, c h a r a c t e r i z e d in that the insulin derivative is sulphated insulin.
8. Use of insulin derivatives which in solution in the

physiological pH range predominantly are present as monomers for the formulation of insulin preparations for non-parenteral administration.

1/1




Fig. 1

INTERNATIONAL SEARCH REPORT

International Application No. **PCT/DK87/00038**

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC <div style="display: flex; justify-content: space-between; margin-top: 10px;"> A 61 K 37/26 4 </div>		
II. FIELDS SEARCHED		
Minimum Documentation Searched †		
Classification System	Classification Symbols	
IPC 4	A 61 K 9/72, 37/26; C 07 K 7/40	
IPC 3	C 07 C 103/32	
IPC 1	A 61 K 17/02 .../...	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched *		
Chemical Abstracts database Medline database		
III. DOCUMENTS CONSIDERED TO BE RELEVANT *		
Category *	Citation of Document, †† with indication, where appropriate, of the relevant passages †‡	Relevant to Claim No. ‡‡
X	SE, B, 382 452 (NATIONAL RESEARCH DEVELOPMENT CORP.) & NL, 7201179 FR, 2123524 DE, 2204053 CH, 547777 GB, 1381273 US, 3868357 AU, 38213/72 CA, 980765 AU, 472582 BE, 778538 GB, 1381274 US, 3868356 AT, 3395122	1-3, 6, 8
X	US, A, 4 534 894 (CERAMI ET AL) 13 August 1985 & CA, 1208627 .../...	1-3, 7, 8
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: †‡</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
1987-07-14	1987-07-17	
International Searching Authority	Signature of Authorized Officer	
Swedish Patent Office	 Christer Jönsson	

L.E.

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

II

Fields Searched (cont).

US CI 260:112.7;
 424:110, 178;
 514:3, 4;
530:303-305

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claim numbers because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out specifically:

3. ☐ Claim numbers because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
☐ No protest accompanied the payment of additional search fees.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
X	Biological chemistry Hoppe-Seyler. Vol. 366, pp. 521-525, May 1985 (Wolfgang H. Fischer et al) A Shortened Insulin with Full in vitro Potency.	1-4, 8
X	Hoppe-Seylers Zeitschrift für physiologische Chemie. Bd. 356, S. 1397-1404, September 1975, (Hans-Greger Gattner) Darstellung und Eigenschaften von Des-Pentapeptid (B26-30)-Rinderinsulin.	1-3, 5, 8
X	Eur. J. Biochem. 31, 470-473 (1972) (Derek E. Massey et al) The Effect of Acylation on the Molecular Size of Insulin.	1-3, 6, 8
X	Biochemistry 1980, 19, 5926-5931, (Fredrick H. Carpenter et al) Tetrakis(3-nitrotyro sine)) insulin.	1-3, 8
A	US, A, 4 153 689 (HIRAI ET AL) 8 May 1979	1-8
A	EP, A2, 0 128 831 (CAREY MARTIN C ET AL) 19 December 1984	1-8
A	DK, B, 135 268 (TORAY INDUSTRIES INC.) 28 March 1977	1-8